Drugs / Alefacept
Trials 32 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01267643 | May → Dec 2011 | aplastic anemia | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT01163799 | Jul 2010 → Sep 2011 | — | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00653822 | Mar → Jul 2008 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00438802 | Mar 2006 → Aug 2010 | lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00397332 | Oct 2006 → Jan 2013 | chronic graft versus host disease | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT00965458 | Mar 2011 → Mar 2013 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT01226420 | Oct 2010 → Aug 2012 | chronic graft versus host disease | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00808223 | Apr 2009 → Feb 2012 | psoriasis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00543569 | Feb 2008 → Feb 2011 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00617604 | Dec 2007 → Sep 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00376129 | Jan 2006 → Jan 2007 | atopic eczema | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT00301002 | Jun 2005 → Oct 2006 | palmoplantar pustulosis | The Guenther Dermatology Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT00143806 | Oct 2003 → May 2007 | psoriasis | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00150982 | Sep 2003 → Feb 2005 | psoriasis | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00659412 | Sep 2003 → Mar 2005 | psoriatic arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT00361413 | Jun 2006 → Jul 2013 | graft versus host disease | Hadassah Medical Organization | Terminated | No outcome recorded |
| Phase 3 | NCT00673556 | Oct 2003 → May 2005 | psoriasis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00674063 | Jul 2003 → Apr 2004 | psoriasis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00233662 | Dec 2002 → Dec 2005 | psoriasis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT00692172 | Dec 2001 → Nov 2004 | psoriasis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT00815633 | Dec 2008 → Jun 2009 | pityriasis rubra pilaris | Joshua Zeichner | Terminated | No outcome recorded |
| Phase 4 | NCT00655564 | May 2008 → Dec 2009 | psoriasis | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT00953329 | Feb → Dec 2008 | psoriasis | John Murray | Terminated | No outcome recorded |
| Phase 4 | NCT00832585 | Jan 2008 → Sep 2009 | atopic eczema | Rush University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00168753 | Jul 2004 → Mar 2005 | psoriasis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00794807 | Feb 2004 → Dec 2005 | psoriasis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT01433770 | Oct 2011 → Oct 2013 | — | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| — | NCT01319851 | Sep 2010 → Sep 2013 | Chediak-Higashi syndrome, Diamond-Blackfan anemia, Fanconi anemia, Glanzmann thrombasthenia +8 | Emory University | Terminated | No outcome recorded |
| — | NCT00678470 | Sep 2007 → Jun 2011 | psoriasis | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00167102 | Jul 2005 → Feb 2008 | alopecia areata | University of Minnesota | Completed | No outcome recorded |
| — | NCT00422617 | Jan → Nov 2005 | psoriasis | Uni-Pharma | Completed | No outcome recorded |
| — | NCT00407342 | Feb → Jun 2004 | psoriasis | Medical University of Graz | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00135733 Comparator | Apr → Dec 2004 | lichen planus | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00658606 Comparator | Oct 2007 → Dec 2009 | psoriasis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00493324 Background | Jul 2007 → Jul 2008 | psoriasis | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alefacept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00658606 ↗33 |
| Known as | Amevive | “Alefacept (AMEVIVE®) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3)...” NCT00397332 ↗5“In Vivo Induction of T Cell Apoptosis by Alefacept (LFA-3/IgG1 Fusion Protein, Amevive) in Patients With Psoriasis: An Investigator-Initiated, Open-Label, Mechanism of Action Study” NCT00150982 ↗ “Alefacept (AMEVIVE®) is an immunosuppressive dimeric fusion protein.” NCT00361413 ↗ “Alefacept (Amevive)” NCT00422617 ↗ “Amevive (Alefacept)” NCT00135733 ↗ |
| Known as | BG-9273 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201571 ↗ |
| Known as | BG-9712 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201571 ↗ |
| Known as | Human lfa-3igg fusion protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201571 ↗ |
| Known as | LFA-3CD2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201571 ↗ |
| Known as | LFA-3TIP | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201571 ↗ |
| Action | Inhibit | “By blocking the activity and decreasing the number of T-cells Alefacept may help improve the disease” NCT00135733 ↗ |
| Modality | Protein / enzyme biologic | “LFA-3/IgG1 Fusion Protein” NCT00150982 ↗ |
| Route | Intravenous | “given alefacept 7.5 mg intravenously on a weekly basis for 12 weeks” NCT00150982 ↗ |
| Target | CD2 | “specifically binding to the lymphocyte antigen, CD2” NCT00361413 ↗ |